<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872582</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-078-01</org_study_id>
    <nct_id>NCT04872582</nct_id>
  </id_info>
  <brief_title>PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy</brief_title>
  <official_title>PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapyï¼šA Single Center, Single Arm, Phase II Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XIANG YANQUN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with&#xD;
      bevacizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma after failure&#xD;
      of first-line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of cendilizumab combined with bevacizumab in the&#xD;
      treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC) after first-line&#xD;
      chemotherapy failure. The primary end point is objective response rate (ORR), the secondary&#xD;
      end points are overall survival (OS), progression-free survival (PFS), median time to&#xD;
      response (MTTR), duration of response (DOR), adverse effects and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of patients whose tumors shrink by a certain amount and remain in place for a certain amount of time, including complete response (CR) and partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Patients in clinical trials were randomized to the time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>36/5000 The time from the commencement of a randomized clinical trial to the progression of tumorigenesis (in any respect) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median time to response (MTTR)</measure>
    <time_frame>2 years</time_frame>
    <description>From the random date up to the median time of the first assessment of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>The time between the first assessment of a tumor as CR or PR and the first assessment of PD or death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <condition>Metastatic Nasopharyngeal Carcinoma</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>PD-1 immune checkpoint inhibitor combined with bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab</intervention_name>
    <description>combined</description>
    <arm_group_label>PD-1 immune checkpoint inhibitor combined with bevacizumab</arm_group_label>
    <other_name>Sintilimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with metastatic or recurrent nasopharyngeal carcinoma are not&#xD;
             suitable for radical local treatment.&#xD;
&#xD;
          -  Previous failure of first-line platinum-containing chemotherapy (single drug or&#xD;
             combination).&#xD;
&#xD;
          -  Previously diagnosed WHO classification type II or III by histological pathology.&#xD;
&#xD;
          -  At least one measurable lesion (according to RECIST1.1).&#xD;
&#xD;
          -  Age between 18 and 70.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1, and life expectation at least 3 months.&#xD;
&#xD;
          -  Enough blood test.&#xD;
&#xD;
          -  Participate voluntarily and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed WHO classification type I by histological pathology.&#xD;
&#xD;
          -  Previous use of bevacizumab.&#xD;
&#xD;
          -  Previous use of sorafenib, apatinib, sunitinib, amlotinib and other small molecule&#xD;
             --vascular targeting drugs.&#xD;
&#xD;
          -  Previous treatment with PD-1 mmune checkpoint inhibitor.&#xD;
&#xD;
          -  Necrotizing lesions were found within the first 4 weeks, or the risk of massive&#xD;
             bleeding.&#xD;
&#xD;
          -  A history of interstitial pneumonia or other autoimmune diseases.&#xD;
&#xD;
          -  Sever infection.&#xD;
&#xD;
          -  Sever heart disease.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Allogeneic organ transplantation&#xD;
&#xD;
          -  Malignancy other than nasopharyngeal carcinoma.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Received other test drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqun Xiang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanqun Xiang, Dr.</last_name>
    <phone>+86-18666096623</phone>
    <email>xiangyq@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weixiong Xia, Dr.</last_name>
    <phone>+86-18520415699</phone>
    <email>xiawx@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yanqun Xiang</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanqun Xiang, Dr.</last_name>
      <phone>+86-18666096623</phone>
      <email>xiangyq@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Weixiong Xia, Dr.</last_name>
      <phone>+86-18520415699</phone>
      <email>xiawx@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 2, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>XIANG YANQUN</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

